Starton Therapeutics Announces Successful Results in STAR-LLD Toxicology Study: No Myelosuppression and Excellent Tolerability
Study marks completion of IND-enabling work for STAR-LLD in multiple myeloma and chronic lymphocytic leukemia (CLL)PARAMUS, N.J., Sept. 30, 2021...